FosPeg® PDT alters the EBV miRNAs and LMP1 protein expression in EBV positive nasopharyngeal carcinoma cells

Ricky W.K. Wu; Ellie S.M. Chu; Zheng Huang; C. S. Xu; C. W. Ip; Christine M.N. Yow

doi:10.1016/j.jphotobiol.2013.07.020

FosPeg® PDT alters the EBV miRNAs and LMP1 protein expression in EBV positive nasopharyngeal carcinoma cells

Ricky W.K. Wu, Ellie S.M. Chu, Zheng Huang, C. S. Xu, C. W. Ip, Christine M.N. Yow^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

16 Citations (Scopus)

Abstract

Nasopharyngeal carcinoma (NPC) is one of the top ten cancers highly prevalent in Hong Kong and South China. Epstein-Barr virus (EBV) infection contributes to the tumorigenesis of NPC through the expression of different viral proteins. Among these, Latent Membrane Protein 1(LMP1) is the major oncoprotein expressed by EBV. Foscan® (Biolitec AG), m- tetrahydroxyphenylchlorin (mTHPC)-based photosensitizing drug, has been used in the photodynamic therapy (PDT) for head and neck cancers. FosPeg® (Biolitec AG) is a new formulation of mTHPC contained in PEGylated liposomes with optimized distribution properties. In this in vitro study, the potential of FosPeg®-PDT on human EBV positive NPC cell (c666-1) and EBV negative cells (HK1 and CNE2) were investigated. Effects of FosPeg®-PDT on the expression of EBV BART miRNAs (EBV miRNA BART 1-5p, BART 16, and BART 17-5p), LMP1 mRNA and proteins on c666-1 cells were also elucidated. The killing efficacy of FosPeg®-PDT on NPC cells were determined by MTT assay after LED activation. Effects of FosPeg®-PDT on the expression of LMP1 mRNA and protein were examined by real time PCR and western blot analysis. FosPeg®-PDT demonstrated its antitumor effect on c666-1 cells in a drug and light dose dependent manner. LD₃₀, LD₅₀ and LD₇₀ were achieved by applying LED activation (3 J/cm²) at 4 h post incubated cells with 0.05 μg/ml, 0.07 μg/ml and 0.3 μg/ml FosPeg®, respectively. Up-regulation of both LMP1 mRNA and protein were observed after FosPeg®-PDT in a dose dependent manner. FosPeg®-PDT exerted antitumor effect on c666-1 cells through up-regulation of LMP1 protein. Understanding the mechanism of FosPeg®-PDT may help to develop better strategies for the treatment of NPC.

Original language	English
Pages (from-to)	114-122
Number of pages	9
Journal	Journal of Photochemistry and Photobiology B: Biology
Volume	127
Early online date	6 Aug 2013
DOIs	https://doi.org/10.1016/j.jphotobiol.2013.07.020
Publication status	Published - 5 Oct 2013
Externally published	Yes

Keywords

EBV miRNAs
FosPeg®
LMP1 protein
PDT

ASJC Scopus subject areas

Radiation
Radiological and Ultrasound Technology
Biophysics
Radiology Nuclear Medicine and imaging

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Documents and Links

10.1016/j.jphotobiol.2013.07.020

Cite this

@article{a3e475234eea49308a590246916c4dd1,

title = "FosPeg{\textregistered} PDT alters the EBV miRNAs and LMP1 protein expression in EBV positive nasopharyngeal carcinoma cells",

abstract = "Nasopharyngeal carcinoma (NPC) is one of the top ten cancers highly prevalent in Hong Kong and South China. Epstein-Barr virus (EBV) infection contributes to the tumorigenesis of NPC through the expression of different viral proteins. Among these, Latent Membrane Protein 1(LMP1) is the major oncoprotein expressed by EBV. Foscan{\textregistered} (Biolitec AG), m- tetrahydroxyphenylchlorin (mTHPC)-based photosensitizing drug, has been used in the photodynamic therapy (PDT) for head and neck cancers. FosPeg{\textregistered} (Biolitec AG) is a new formulation of mTHPC contained in PEGylated liposomes with optimized distribution properties. In this in vitro study, the potential of FosPeg{\textregistered}-PDT on human EBV positive NPC cell (c666-1) and EBV negative cells (HK1 and CNE2) were investigated. Effects of FosPeg{\textregistered}-PDT on the expression of EBV BART miRNAs (EBV miRNA BART 1-5p, BART 16, and BART 17-5p), LMP1 mRNA and proteins on c666-1 cells were also elucidated. The killing efficacy of FosPeg{\textregistered}-PDT on NPC cells were determined by MTT assay after LED activation. Effects of FosPeg{\textregistered}-PDT on the expression of LMP1 mRNA and protein were examined by real time PCR and western blot analysis. FosPeg{\textregistered}-PDT demonstrated its antitumor effect on c666-1 cells in a drug and light dose dependent manner. LD30, LD50 and LD70 were achieved by applying LED activation (3 J/cm2) at 4 h post incubated cells with 0.05 μg/ml, 0.07 μg/ml and 0.3 μg/ml FosPeg{\textregistered}, respectively. Up-regulation of both LMP1 mRNA and protein were observed after FosPeg{\textregistered}-PDT in a dose dependent manner. FosPeg{\textregistered}-PDT exerted antitumor effect on c666-1 cells through up-regulation of LMP1 protein. Understanding the mechanism of FosPeg{\textregistered}-PDT may help to develop better strategies for the treatment of NPC.",

keywords = "EBV miRNAs, FosPeg{\textregistered}, LMP1 protein, PDT",

author = "Wu, {Ricky W.K.} and Chu, {Ellie S.M.} and Zheng Huang and Xu, {C. S.} and Ip, {C. W.} and Yow, {Christine M.N.}",

year = "2013",

month = oct,

day = "5",

doi = "10.1016/j.jphotobiol.2013.07.020",

language = "English",

volume = "127",

pages = "114--122",

journal = "Journal of Photochemistry and Photobiology B: Biology",

issn = "1011-1344",

publisher = "Elsevier B.V.",

}

TY - JOUR

T1 - FosPeg® PDT alters the EBV miRNAs and LMP1 protein expression in EBV positive nasopharyngeal carcinoma cells

AU - Wu, Ricky W.K.

AU - Chu, Ellie S.M.

AU - Huang, Zheng

AU - Xu, C. S.

AU - Ip, C. W.

AU - Yow, Christine M.N.

PY - 2013/10/5

Y1 - 2013/10/5

N2 - Nasopharyngeal carcinoma (NPC) is one of the top ten cancers highly prevalent in Hong Kong and South China. Epstein-Barr virus (EBV) infection contributes to the tumorigenesis of NPC through the expression of different viral proteins. Among these, Latent Membrane Protein 1(LMP1) is the major oncoprotein expressed by EBV. Foscan® (Biolitec AG), m- tetrahydroxyphenylchlorin (mTHPC)-based photosensitizing drug, has been used in the photodynamic therapy (PDT) for head and neck cancers. FosPeg® (Biolitec AG) is a new formulation of mTHPC contained in PEGylated liposomes with optimized distribution properties. In this in vitro study, the potential of FosPeg®-PDT on human EBV positive NPC cell (c666-1) and EBV negative cells (HK1 and CNE2) were investigated. Effects of FosPeg®-PDT on the expression of EBV BART miRNAs (EBV miRNA BART 1-5p, BART 16, and BART 17-5p), LMP1 mRNA and proteins on c666-1 cells were also elucidated. The killing efficacy of FosPeg®-PDT on NPC cells were determined by MTT assay after LED activation. Effects of FosPeg®-PDT on the expression of LMP1 mRNA and protein were examined by real time PCR and western blot analysis. FosPeg®-PDT demonstrated its antitumor effect on c666-1 cells in a drug and light dose dependent manner. LD30, LD50 and LD70 were achieved by applying LED activation (3 J/cm2) at 4 h post incubated cells with 0.05 μg/ml, 0.07 μg/ml and 0.3 μg/ml FosPeg®, respectively. Up-regulation of both LMP1 mRNA and protein were observed after FosPeg®-PDT in a dose dependent manner. FosPeg®-PDT exerted antitumor effect on c666-1 cells through up-regulation of LMP1 protein. Understanding the mechanism of FosPeg®-PDT may help to develop better strategies for the treatment of NPC.

AB - Nasopharyngeal carcinoma (NPC) is one of the top ten cancers highly prevalent in Hong Kong and South China. Epstein-Barr virus (EBV) infection contributes to the tumorigenesis of NPC through the expression of different viral proteins. Among these, Latent Membrane Protein 1(LMP1) is the major oncoprotein expressed by EBV. Foscan® (Biolitec AG), m- tetrahydroxyphenylchlorin (mTHPC)-based photosensitizing drug, has been used in the photodynamic therapy (PDT) for head and neck cancers. FosPeg® (Biolitec AG) is a new formulation of mTHPC contained in PEGylated liposomes with optimized distribution properties. In this in vitro study, the potential of FosPeg®-PDT on human EBV positive NPC cell (c666-1) and EBV negative cells (HK1 and CNE2) were investigated. Effects of FosPeg®-PDT on the expression of EBV BART miRNAs (EBV miRNA BART 1-5p, BART 16, and BART 17-5p), LMP1 mRNA and proteins on c666-1 cells were also elucidated. The killing efficacy of FosPeg®-PDT on NPC cells were determined by MTT assay after LED activation. Effects of FosPeg®-PDT on the expression of LMP1 mRNA and protein were examined by real time PCR and western blot analysis. FosPeg®-PDT demonstrated its antitumor effect on c666-1 cells in a drug and light dose dependent manner. LD30, LD50 and LD70 were achieved by applying LED activation (3 J/cm2) at 4 h post incubated cells with 0.05 μg/ml, 0.07 μg/ml and 0.3 μg/ml FosPeg®, respectively. Up-regulation of both LMP1 mRNA and protein were observed after FosPeg®-PDT in a dose dependent manner. FosPeg®-PDT exerted antitumor effect on c666-1 cells through up-regulation of LMP1 protein. Understanding the mechanism of FosPeg®-PDT may help to develop better strategies for the treatment of NPC.

KW - EBV miRNAs

KW - FosPeg®

KW - LMP1 protein

KW - PDT

U2 - 10.1016/j.jphotobiol.2013.07.020

DO - 10.1016/j.jphotobiol.2013.07.020

M3 - Article

C2 - 24013466

AN - SCOPUS:84883518628

SN - 1011-1344

VL - 127

SP - 114

EP - 122

JO - Journal of Photochemistry and Photobiology B: Biology

JF - Journal of Photochemistry and Photobiology B: Biology

ER -

FosPeg® PDT alters the EBV miRNAs and LMP1 protein expression in EBV positive nasopharyngeal carcinoma cells

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Documents and Links

Fingerprint

Cite this